Genetic variation: Effect on prostate cancer

Tristan M. Sissung, Douglas K. Price, Marzia Del Re, Ariel M. Ley, Elisa Giovannetti, William D. Figg*, Romano Danesi

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

28 Scopus citations


The crucial role of androgens in the development of prostate cancer is well established. The aim of this review is to examine the role of constitutional (germline) and tumor-specific (somatic) polymorphisms within important regulatory genes of prostate cancer. These include genes encoding enzymes of the androgen biosynthetic pathway, the androgen receptor gene, genes that encode proteins of the signal transduction pathways that may have a role in disease progression and survival, and genes involved in prostate cancer angiogenesis. Characterization of deregulated pathways critical to cancer cell growth have lead to the development of new treatments, including the CYP17 inhibitor abiraterone and clinical trials using novel drugs that are ongoing or recently completed [1]. The pharmacogenetics of the drugs used to treat prostate cancer will also be addressed. This review will define how germline polymorphisms are known affect a multitude of pathways, and therefore phenotypes, in prostate cancer etiology, progression, and treatment.

Original languageEnglish
Pages (from-to)446-456
Number of pages11
JournalBiochimica et Biophysica Acta - Reviews on Cancer
Issue number2
StatePublished - 1 Dec 2014
Externally publishedYes


  • Androgen deprivation therapy
  • Chemotherapy
  • Pharmacogenomics
  • Prostate cancer
  • Steroid


Dive into the research topics of 'Genetic variation: Effect on prostate cancer'. Together they form a unique fingerprint.

Cite this